PR Newswire All News ReleasesQwen · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 16:16:00·⟳ 抓取 16:16:19 +19s·⚡ 决策 08-27 16:18:07 +1m48s·61.2 天前
律所发布Replimune证券欺诈集体诉讼投资者招募公告，非新增负面事件
本条信号是律所通过PR Newswire发布的证券集体诉讼首席原告招募广告，属于美国证券市场极为常见的律师营销类新闻稿。底层负面事件（FDA对Replimune RP1-104 BLA申请的研究设计关注及可能拒绝）发生在2026年4月10日之前（集体诉讼期间截止日），距今已4.5个月。本条新闻稿不包含任何新增的监管行动、临床数据、公司声明或市场事件，仅为对已有诉讼的程序性提醒和投资者招募。无论查行情、查KB还是查Web，都不可能改变'无新增可交易事实'的结论。
📄 原文PR Newswire All News Releases↗ 原文
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigati…
不做 Replimune Group（REPL.US）
本条为律所首席原告招募广告，底层负面事件（FDA可能拒绝RP1-104 BLA）已于2026年4月发生并被市场定价，距今4.5个月。无新增监管行动、无新数据、无公司新声明，不构成可交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
PR Newswire上的律所招募公告是美国证券集体诉讼的标准化营销流程，每当上市公司因负面事件股价下跌后，数十家律所会批量发布此类新闻稿招募首席原告。本条的集体诉讼期间为2025年10月20日至2026年4月10日，表明底层负面事件（FDA可能拒绝BLA）已在约4.5个月前发生并被市场充分消化。本条不携带任何新增事实、新监管决定或新数据，属于典型的过期事件回声，不具备交易价值。
🔎 新鲜度:最早出现 2026-04-10 · 扩散 high · price-in 风险 high ↗
先例如何影响了这次决策
对本次决策的影响:无需先例研究——本条不构成可交易催化，是过期事件的律所营销回声
工具调用 · 历史记录,结果未知(1 种)
- fetch_decision_experience · 结果未知
原文全文
展开原文 · 2,772 字
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: October 20, 2025 to April 10, 2026
DEADLINE: October 5, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune failed to address study design concerns the FDA had previously communicated about its Biologics License Application ("BLA"). The Company submitted data from an unplanned analysis of the RP1-104 study to the FDA which included only 10% of the planned study enrollment. Due to these actions, the FDA was likely to reject the Company's BLA. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Replimune, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: October 20, 2025 to April 10, 2026
DEADLINE: October 5, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune failed to address study design concerns the FDA had previously communicated about its Biologics License Application ("BLA"). The Company submitted data from an unplanned analysis of the RP1-104 study to the FDA which included only 10% of the planned study enrollment. Due to these actions, the FDA was likely to reject the Company's BLA. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Replimune, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。